Skip to main content

Abstract

We examined the effect of heat-killed Lactobacillus brevis (L. brevis) SBC8803 on the development of alcoholic liver disease using ethanol-containing diet-fed mice. Heat-killed L. brevis was orally administered at a dose of 100 or 500 mg/kg once a day for 35 days. Alcoholic liver injury was examined by measuring the activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in a serum, and the alcoholic fatty liver was assessed from the content of triglyceride (TG) and total cholesterol in the liver. Quantitative RT-PCR was used to examine mRNA expression of tumor necrosis factor (TNF)-alpha, sterol regulatory element-binding protein (SREBP)-1, SREBP-2, and peroxisome proliferator-activated receptor alpha (PPARalpha) in the liver, as well as E-cadherin, Zonula occludens 1 (ZO-1), and heat shock protein (Hsp) 25 in the small intestine. Oral administration of L. brevis significantly inhibited an increase in the level of serum ALT and AST, as well as the content of TG and total cholesterol in the liver caused by ethanol intake. L. brevis supplementation suppressed the overexpression of TNF-alpha, SREBP-1, and SREBP-2 mRNA in the liver induced by ethanol intake and up-regulated the expression of Hsp25 mRNA in the small intestine. These results suggest that L. brevis ameliorated the ethanol-induced liver injury and the fatty liver by suppressing the up-regulation of TNF-alpha and SREBPs in the liver. We speculate that the inhibition of TNF-alpha and SREBPs up-regulation by L. brevis is due to the inhibition of gut-derived endotoxin migration into the liver through the enhancement of intestinal barrier function by the induction of cytoprotective Hsps.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus brevisImproved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus brevisIncreased Expression of Heat Shock Protein 25Beneficial
Small
Lactobacillus brevisReduced Elevated Liver EnzymesBeneficial
Moderate
Lactobacillus brevisReduced Liver Triglyceride ContentBeneficial
Moderate
Lactobacillus brevisReduced TNF-alpha Gene ExpressionBeneficial
Moderate
Lactobacillus brevis HA-112Increased Small Intestine Hsp25 mRNA ExpressionBeneficial
Small
Lactobacillus brevis HA-112Reduced Liver Enzyme LevelsBeneficial
Large
Lactobacillus brevis HA-112Reduced TNF-α LevelsBeneficial
Moderate
Lactobacillus brevis KABP™-052Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus brevis KABP™-052Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus brevis KABP™-052Reduced Liver Enzyme LevelsBeneficial
Large
Lactobacillus brevis KABP™-052Reduced Liver FatBeneficial
Large
Lactobacillus brevis LB01Increased Small Intestine Hsp25 mRNA ExpressionBeneficial
Small
Lactobacillus brevis LB01Reduced Liver CholesterolBeneficial
Large
Lactobacillus brevis LB01Reduced Liver Enzyme LevelsBeneficial
Large
Lactobacillus brevis LB01Reduced Liver TriglyceridesBeneficial
Large
Lactobacillus brevis LB01Reduced SREBP-1 ExpressionBeneficial
Moderate
Lactobacillus brevis LB01Reduced SREBP-2 ExpressionBeneficial
Moderate
Lactobacillus brevis LB01Reduced TNF-alpha Gene ExpressionBeneficial
Moderate
Lactobacillus brevis Lbr-35Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus brevis Lbr-35Reduced Liver Enzyme LevelsBeneficial
Large
Lactobacillus brevis MAK11L82BImproved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced Hepatic Fat AccumulationBeneficial
Large
Lactobacillus brevis MAK11L82BReduced Inflammatory Marker ExpressionBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced Liver Enzyme LevelsBeneficial
Large
Lactobacillus brevis SBC8803Increased Small Intestine Hsp25 mRNA ExpressionBeneficial
Small
Lactobacillus brevis SD-5214Increased Small Intestine Hsp25 mRNA ExpressionBeneficial
Small
Lactobacillus brevis SD-5214Reduced Liver Injury IndicatorsBeneficial
Large
Lactobacillus brevis UALbr-02Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus brevis UALbr-02Improvement in Alcoholic Liver DiseaseBeneficial
Large
Lactobacillus brevis UALbr-02Reduced Inflammatory MarkersBeneficial
Moderate
Lactobacillus brevis VPro 18Reduced Aminotransferase LevelsBeneficial
Large
Lactobacillus brevis VPro 18Reduced AST LevelsBeneficial
Large
Lactobacillus brevis VPro 18Reduced Liver Cholesterol ContentBeneficial
Large
Lactobacillus brevis VPro 18Reduced Liver Fat ContentBeneficial
Large
Lactobacillus brevis VPro 18Reduced Liver SREBP-1 mRNA LevelsBeneficial
Moderate
Lactobacillus brevis VPro 18Reduced Liver SREBP-2 mRNA LevelsBeneficial
Moderate
Lactobacillus brevis VPro 18Reduced TNF-α LevelsBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.